Patents Assigned to ANTECIP BIOVENTURES II LLC
  • Neridronic acid for treating bone marrow lesion
    Patent number: 9770457
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions such as bone marrow lesion.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: September 26, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
    Patent number: 9763932
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: August 12, 2016
    Date of Patent: September 19, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Osteoclast inhibitors for knee conditions
    Patent number: 9717747
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: August 1, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventors: Herriot Tabuteau, Graeme Jones
  • Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
    Patent number: 9707191
    Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: July 18, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Neridronic acid for treating complex regional pain syndrome
    Patent number: 9707245
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions such as complex regional pain syndrome.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: July 18, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions for administration of zoledronic acid or related compounds for treating low back pain
    Patent number: 9707247
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, such as zoledronic acid in an acid or a salt form, or in a molecular complex can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: July 18, 2017
    Assignee: Antecip Bioventures II LLC
    Inventor: Herriot Tabuteau
  • Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
    Patent number: 9700553
    Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: July 11, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
    Patent number: 9700528
    Abstract: This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: July 11, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
    Patent number: 9700570
    Abstract: Therapeutic compositions comprising substituted imidazole or imidazolium compounds may be used for a number of medical purposes, such as treatment of undesirable conditions or diseases, including disease or conditions related to bone, cancer, and/or pain such as complex regional pain syndrome.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: July 11, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Osteoclast inhibitors for knee conditions
    Patent number: 9694022
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: July 4, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Methods for the safe administration of imidazole or imidazolium compounds
    Patent number: 9694023
    Abstract: Methods for the safe administration of imidazole or imidazolium compounds, and conditions that may be treated by these methods, are described herein.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: July 4, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteu
  • Methods using RANK/RANKL antagonist antibodies for treating pain
    Patent number: 9688765
    Abstract: Disclosed herein are methods of treating pain using comprising RANK/RANKL antagonists.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: June 27, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
    Patent number: 9675626
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions such as complex regional pain syndrome.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: June 13, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
    Patent number: 9669040
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions such as complex regional pain syndrome.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: June 6, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
    Patent number: 9662343
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions such as complex regional pain syndrome.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: May 30, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Neridronic acid molecular complex for treating complex regional pain syndrome
    Patent number: 9655908
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, such as zoledronic acid and neridronic acid in an acid or a salt form, or in a molecular complex can be used to treat or alleviate pain or related conditions, such as complex regional pain syndrome.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: May 23, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Osteoclast inhibitors for bone marrow lesions
    Patent number: 9623038
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: April 18, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventors: Herriot Tabuteau, Graeme Jones
  • Osteoclast inhibitors for knee conditions
    Patent number: 9623037
    Abstract: Oral dosage forms of osteoclast inhibitors, such as nitrogen-containing bisphosphonates, can be used to treat or alleviate pain or related conditions.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: April 18, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Osteoclast inhibitors such as zoledronic acid for low back pain treatment
    Patent number: 9623036
    Abstract: Methods for the safe administration of imidazole or imidazolium compounds, and conditions that may be treated by these methods, are described herein.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: April 18, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventors: Herriot Tabuteau, Jaro I. Karppinen
  • Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
    Patent number: 9616077
    Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions. The oral bioavailability of zoledronic acid can be enhanced by administering the zoledronic acid in the disodium salt form.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: April 11, 2017
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau